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Secretagogin is a calcium binding protein (CBP) highly expressed in neuroendocrine cells.
It has been shown to be involved in insulin secretion from pancreatic beta cells and is a
strong candidate as a biomarker for endocrine tumors, stroke, and eventually psychiatric
conditions. Secretagogin has been hypothesized to exert a neuroprotective role in neu-
rodegenerative diseases like Alzheimer’s disease. The expression pattern of Secretagogin
is not conserved from rodents to humans. We used brain tissue and primary neuronal cell
cultures from rat to further characterize this CBP in rodents and to perform a few func-
tional assays in vitro. Immunohistochemistry on rat brain slices revealed a high density of
Secretagogin-positive cells in distinct brain regions. Secretagogin was found in the cytosol
or associated with subcellular compartments.We tested primary neuronal cultures for their
suitability as model systems to further investigate functional properties of Secretagogin.
These cultures can easily be manipulated by treatment with drugs or by transfection with
test constructs interfering with signaling cascades that might be linked to the cellular func-
tion of Secretagogin. We show that, like in pancreatic beta cells and insulinoma cell lines,
also in neurons the expression level of Secretagogin is dependent on extracellular insulin
and glucose. Further, we show also for rat brain neuronal tissue that Secretagogin interacts
with the microtubule-associated proteinTau and that this interaction is dependent on Ca2+.
Future studies should aim to study in further detail the molecular properties and function
of Secretagogin in individual neuronal cell types, in particular the subcellular localization
and trafficking of this protein and a possible active secretion by neurons.
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INTRODUCTION
Calcium (Ca2+) is a universal second messenger, which plays a
crucial role in signal transduction in many fundamental physi-
ological processes. In the central nervous system (CNS) calcium
signaling is utilized by neurons to control membrane excitability,
neurotransmitter release, gene expression, cellular growth, differ-
entiation, and cell death. Different variants of high transient and
local Ca2+ concentrations in neurons play an important role in
information processing (Niggli and Shirokova, 2007). Intracellular
Ca2+ waves are also observed in glia cells, a finding that currently
reshapes the known role of glia cells from neuronal supporters to
active signal transmitting cells (Dityatev and Rusakov, 2011).
Calcium binding proteins (CBPs) therefore play a pivotal role
in sensing and transducing these signals into cellular responses like
Abbreviations: CBP, calcium binding protein; nCBP, neuronal calcium bind-
ing protein; NCS, neuronal calcium sensor; SCGN, Secretagogin (human); Scgn,
Secretagogin (rat).
the modulation of ion channel or receptor function, enzyme activ-
ity, neurotransmitter release, and many more (Yanez et al., 2012).
The huge number of identified CBPs relates to their different roles
and substrate specificity. N-terminal myristoylation and specific
protein–protein interactions mediate their subcellular targeting
and substrate specificity. Calcium also plays an important role in
the secretory pathway of neurons regulating processes like vesi-
cle budding and fusion, vesicle trafficking between Golgi stacks,
TGN sorting, and the regulation of SNARE proteins. Some CBPs
like calmodulin are possibly present in all neuronal cell types.
Other known neuronal CBPs (nCBPs) are present only in certain
subpopulations of neurons (Mikhaylova et al., 2011). From the
functional point of view two major groups of nCBPs have tradi-
tionally been distinguished: Ca2+ buffers, which bind Ca2+ with
high affinity without undergoing major conformational changes,
and Ca2+ sensors (NCS), which need higher Ca2+ pulses for
activation and undergo substantial conformational changes upon
binding to Ca2+. These activated states lead to the exposure of
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interaction motifs with downstream targets and frequently initiate
signal transduction cascades (Burgoyne and Haynes, 2012). One
of the best-known and well-studied examples also in this respect
is again calmodulin. The distinction between calcium buffers and
calcium sensors is still valid from a functional viewpoint, but it
becomes increasingly difficult to assign individual CBPs selectively
to one or the other group. The more experimental evidence is avail-
able, the more it becomes clear that CBPs might have dual or more
functional properties (Schwaller, 2009; Mikhaylova et al., 2011).
A large body of evidence has indicated that unbalanced Ca2+
homeostasis contributes to the development of neurological and
neurodegenerative diseases (Braunewell, 2005; Yu et al., 2009;
Demuro et al., 2010; Hermes et al., 2010; Camandola and Mattson,
2011).
Nonetheless, several mechanisms have been developed to con-
trol Ca2+ homeostasis and to prevent cellular damage. Among
these are also nCBPs, which have been reported to display altered
levels in neurodegenerative disorders (Steiner et al., 2011). Apart
from this role in homeostasis, a major task of many nCBPs
is in active signal transduction, where our current knowledge
is restricted to only few representatives and is still frequently
rudimentary.
Most nCBPs exhibit a tissue specific expression pattern in the
mammalian brain. Therefore, they have been used as cell type spe-
cific markers before other ways of identification of cell types in
the CNS became available (Klausberger et al., 2003). Novel nCBPs
are discovered on a regular basis mostly by proteomic screens,
each of them with different developmental and cell type specific
expression patterns.
A more recently identified CBP is Secretagogin, a multi-faceted
protein that is highly expressed in pancreatic beta cells, cells
of the gastrointestinal tract as well as in neuroendocrine cells
of the CNS (Wagner et al., 2000; Gartner et al., 2001; Mul-
der et al., 2009). Secretagogin contains six EF-hand motifs as
potential Ca2+ binding sites, some of which seem to be non-
functional. Structural analysis have revealed some similarities
with the Ca2+ sensor calmodulin (Bitto et al., 2009). Secret-
agogin undergoes conformational changes upon Ca2+ binding
indicating a potential role as a Ca2+ sensor in specialized cells
(Rogstam et al., 2007). Broad screenings by protein arrays have
led to the identification of a variety of Secretagogin interaction
partners that are associated with vesicle fusion (like SNAP-23,
SNAP-25, ARFGAP2, DOC2alpha, rootletin), trafficking (tubu-
lin, KIF5B), enzymatic activity (DDAH-2, ATP-synthase), and
one onco-protein (myeloid leukemia factor 2; Rogstam et al.,
2007;Bauer et al., 2011a,b). Secretagogin has received consider-
able attention due to its significance in insulin secretion from
pancreatic beta cells and as a potential biomarker for the diag-
nosis of stroke and distinct tumors of endocrine origin such as
adenocarcinomas of the stomach, pancreas, prostate, colorectum,
kidney, and lung small cell carcinoma in the blood of patients
(Gartner et al., 2001; Lai et al., 2006; Adolf et al., 2007; Ilhan
et al., 2011; Zurek and Fedora, 2012). Albeit performed stud-
ies on Secretagogin its function is still unclear. By in silico gene
analysis it was previously found that the Secretagogin gene-
promoter sequence might respond to glucose (Skovhus et al.,
2006).
Human and mouse brain has been examined to some extent
for Secretagogin expression in previous studies (Attems et al.,
2008;Mulder et al., 2009, 2010). As the regional expression pattern
turned out to differ significantly between species, we now chose
to characterize the expression of Secretagogin in rat brain to com-
pare with previous studies on mouse and human brain. In order
to perform functional studies we were looking for a primary cell
culture system that expresses endogenous Secretagogin at a high
level and chose the well-established primary culture system of rat
embryonic hippocampal and cortical neurons for in vitro studies
to get a hint of the expression dynamics and functional aspects
of the protein. The tight connection between glucose and insulin,
which is also a basic neuronal trophic factor, let us ask, whether
insulin and glucose levels influence the expression of Secretagogin
in neuronal cells.
Our cell culture system proved to be a suitable model system
to perform more functional assays in the future, last but not least,
because interference of signaling cascades by drug treatment and
tracking the fate and trafficking of proteins by transfection of
these neurons with test constructs (like dominant negative or
non-functional variants of proteins, fluorescent tagged versions
of the protein, and subcellular markers) is technically easy to per-
form and analysis by common biochemical and cell biological
techniques promises relevant results. The in vitro studies can be
extended to neuronal cultures derived from other brain areas that
express high levels of endogenous Secretagogin in order to inves-
tigate cell type specific functional similarities or differences of this
protein.
Since the recent clinical studies on Secretagogin revealed its
potential implication as a novel blood and cerebrospinal fluid bio-
marker, further knowledge on this protein is of major interest also
from the medical point of view.
MATERIALS AND METHODS
PRODUCTION AND PURIFICATION OF SECRETAGOGIN PROTEIN
Human and rat Secretagogin protein was produced and purified
the same way as described previously in Wagner et al. (2000)
and Gartner et al. (2007), respectively. In brief, the entire cod-
ing sequence of the human/rat Secretagogin gene was amplified
by PCR using primers with EcoRI and BamHI at the flanking end
and subsequently cloned into the pGEX-1λT expression vector.
The coding sequence for Secretagogin in this construct is located
downstream of the coding sequence for glutathione S-transferase
separated from GST by a thrombin cleavage site. These constructs
(GST-SCGN and GST-Scgn) were transformed into Escherichia
coli BL21, and after colony selection transformed bacteria were
grown overnight at 37˚C. The next morning the culture was diluted
1:5 and expression of the fusion proteins was induced by addition
of isopropyl-β-d-thiogalactoside (final conc. 10 mM) followed by
incubation for 3 h at 31˚C on a rotating shaker. Afterwards the
bacteria were pelleted, sonicated in ice-cold PBS containing 0.1%
Triton X-100, and a mix of protease inhibitors. The bacterial lysate
was precleared by centrifugation at 12,000 rpm for 10 min and
equilibrated glutathione-Sepharose 4B beads were added to the
obtained supernatant and mixed for 30 min at 4˚C under con-
stant rotation. Following three washes of protein-bound beads
with cold PBS, full-length Secretagogin was released by thrombin
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cleavage. The reaction was incubated for 3 h at RT on a rotating
platform, centrifuged at 1500 rpm, and the resulting supernatant
containing Secretagogin (human or rat) was tested by SDS-PAGE
gel-electrophoresis in order to evaluate the presence of full-length
protein. After protein quantification the purified Secretagogin
protein was frozen at−80˚C until further use.
ANTIBODIES
Rabbit anti-SCGN antiserum was generated against recombinant
Secretagogin protein as described previously and cross-reacts with
the rat ortholog (Wagner et al., 2000; Gartner et al., 2001). We
used dilutions of 1:1000 for immunohistochemistry and 1:5000
for immunoblotting.
The following commercial antibodies were used for immuno-
fluorescence or other techniques as indicated: rabbit anti-pan-TAU
(Cat. No. A 0024, DakoCytomation, Denmark, Glostrup) dil.
1:5000 for immunoblotting; mouse anti-Parvalbumin (Cat. No.
PVG214, Swant, Switzerland) dil. 1:3000; mouse anti-Calbindin
D28k (Cat. No.300, Swant, Switzerland) dil. 1:10,000; mouse anti-
Calretinin (Cat. No. 6B3, Swant, Switzerland) dil. 1:5000; mouse
anti-GRP78 (which was a kind gift from the lab of Prof. Johannes
Berger) dil. 1:100; mouse anti-GM130 (Cat. No. 560257, BD
Biosciences, Franklin Lakes, NJ) dil. 1:100; mouse monoclonal
anti-β-actin (AC-15; Cat. No. NB600-501, Novus Biologicals, Lit-
tleton, CO, USA) for Western blot controls dil. 1:5000. Secondary
antibodies and nuclear staining: DyLight488 goat anti-mouse
(Cat. No. 115-485-1460, Jackson ImmunoResearch, Suffolk, UK)
dil. 1:400; DyLight488 donkey anti-rabbit (Cat. No. 711-485-
1520, Jackson ImmunoResearch) dil. 1:400; Cy3 goat anti-rabbit
(Cat. No. 111-166-003, Jackson ImmunoResearch) dil. 1:500;
DyLight649 donkey anti-guinea pig (Cat. No. 706-495-148, Jack-
son ImmunoResearch) dil. 1:400; DyLight649 donkey anti-rabbit
(Cat. No. 111-196-003, Jackson ImmunoResearch) dil. 1:400; TO-
PRO (Cat. no. T-3605, Invitrogen) dil. 1:500; DAPI (Sigma Cat.
No. D8417) final conc. 1µg/ml in PBS.
RABBIT ANTI-SCGN ANTISERUM SPECIFICITY TEST
In order to confirm specificity of our rabbit anti-human SCGN
antiserum against rat-Scgn, the recombinant purified protein (rat-
Scgn, 267 amino acid residues) was pre-incubated with anti-SCGN
antibody. The reaction was performed at room temperature for
2 h. The resultant solution containing antibody/antigen complexes
was centrifuged at 13,000 rpm for 15 min at 4˚C. The supernatant
was then used in parallel with native untreated antibody for stain-
ing of sections of fixed rat brain. Immunofluorescence staining
and imaging was performed as indicated below. The experiment
was carried out in duplicates.
Further evidence for antiserum specificity was obtained from
a stable cell line expressing human Secretagogin. Jurkat cells were
transfected with full-length human Secretagogin encoding plas-
mid pZeoSV2. Cells, that had stably incorporated the plasmid in
the genome and were expressing the protein at a high level were
chosen for further experiments.
Protein G-Sepharose beads were used to bind rabbit anti-Scgn
antiserum. After washing, beads were incubated with lysates from
sham-transfected and SCGN-expressing Jurkat cells. Following
three washing steps with 0.1% Tween 20 in PBS (TPBS), beads
were eluted in 50 mM triethanolamine, 150 mM NaCl, 0.1% Tween
20, pH 11.2. Eluted fractions were neutralized and loaded onto
a 10% SDS-PAGE gel and transferred to nitrocellulose using a
semi-dry blotting device. Blotted membranes were blocked and
exposed to biotinylated rabbit anti-SCGN antibody followed by
incubation with Streptavidine/HRP for 30 min. Each incubation
step was followed by two washes with TPBS for 10 min. The blot
was finally developed with chemiluminescent reagent and bands
were visualized with a Lumi Imager F1.
IMMUNOHISTOCHEMISTRY OF RAT BRAIN SLICES
Six-week-old rats were deeply anesthetized with Equithesin and
perfused transcardially with 0.9% NaCl, followed by a mixture of
4% paraformaldehyde, and 15% picric acid in 0.1 M phosphate
buffer (PB; pH 7.2–7.4) using a peristaltic pump. Brains were left
in situ for 10–15 min, removed, and kept in 0.1 M PB with 0.05%
sodium azide for a few days at 4˚C. Serial coronal sections of 50µm
were cut on the vibratome. Sections were kept in PB containing
0.05% sodium azide at 4˚C until staining.
Immunofluorescence experiments were carried out accord-
ing to previously published procedures (Klausberger et al., 2003;
Vasiljevic et al., 2011). Briefly, free-floating sections were incu-
bated in 0.1% Triton X-100/PB for 30 min, blocked in 20%
normal horse serum diluted in Tris-buffered saline (50 mM
Tris, pH 7.2, 0.85% NaCl) for 2 h, and then incubated in a
solution containing a mixture of primary antibodies (rabbit
anti-Secretagogin antibody, dil. 1:5000; mouse monoclonal anti-
Parvalbumin antibody; mouse monoclonal anti-Calbindin D28k
antibody; mouse monoclonal anti-Calretinin antibody) for 48 h
at 4˚C. Sections were washed and subsequently incubated for
4 h at room temperature with appropriate secondary antibod-
ies conjugated either to Alexa Fluor 488 (anti-rabbit; Invitro-
gen Molecular Probes, dil. 1:1000) or Cy3 (anti-mouse; Jackson
ImmunoResearch Laboratories, dil. 1:400). All antibodies were
diluted in TBS containing 0.1% Triton X-100 and 1% normal
horse serum. After washing in TBS (50 mM Tris buffer, pH
7.4), sections were mounted in Aqua PolyMount (Polysciences
Europe, Eppelheim, Germany), and left to polymerize at 4˚C
over night. Sections were examined with a Leica TCS SP5 II
confocal microscope (Leica Microsystems GmbH, Wetzlar, Ger-
many). All antibodies were tested for optimal dilution, and sec-
ondary antibodies were tested for cross-reactivity and non-specific
staining.
IMMUNOHISTOCHEMISTRY OF HUMAN SAMPLES
Brain tissue obtained from routine autopsy was fixed in 4% For-
malin and embedded in paraffin as a routine procedure for the
process of pathological specimens. Tissue sections of 4 mm were
deparaffinized with xylol, passed through a graded ethanol series
and finally washed in distilled water. Endogenous peroxidase was
blocked with 3% H2O2 in methanol for 10 min. Following anti-
gen retrieval in citrate buffer, pH 6.0 for 60 min at 96˚C, slides
were washed in Tris-buffered saline (TBS), and blocked with 10%
FCS for 10 min. The primary antibody was applied for 2 h. After
washing the slide for 10 min in PBS the secondary antibody was
applied and incubated for 1.5 h at RT. Following two washing steps
for 10 min at RT in PBS, the chromogenic substrate DAB was
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applied (EnVision ™Kit DakoCytomation K5007) and the reac-
tion was stopped after 10 min by washing the slide with tap water.
As a counterstain Mayer’s Hemalaun was used for 30 s, which was
washed off by tap water. Finally, slides were exposed to 0.45 M
HCl in 70% EtOH followed by a further wash in water. Sections
were dehydrated in acetyl butyrate and mounted with a coverslip.
Images were taken using a Leica Aristoplan microscope.
PRIMARY RAT CELL CULTURE
Primary neuronal cultures were prepared from rat E18 embryos
(pregnant Sprague-Dawley rats were purchased from Charles
River, Germany). Procedures were carried out in accordance
with animal care guidelines of the Medical University of Vienna,
Austria. Cultures were essentially prepared as neuron/glia co-
cultures as described previously with modifications (Brewer et al.,
1993). Hippocampus and cortex were dissected and individually
trypsinized at 37˚C in a 10 mM HEPES buffered Hank’s bal-
anced salt solution (HBSS; GIBCO Life Technologies, NY, USA).
Tissues were washed three times with ice-cold HBSS and disso-
ciated by trituration. Cortical neurons were additionally sieved
through 100 and 70µm filters (Falcon). Neurons were plated at
a density of ∼52,500 cells/cm2 into 24-well culture plates. For
Western blot analysis and real-time quantitative PCR (RT-qPCR)
six-well culture plates were seeded at the same density. Cells
were left to attach overnight in MEM medium containing 10%
horse serum, 1 mM sodium pyruvate (all from GIBCO), 1.2%
d-glucose (Sigma), 100 U/ml penicillin together with 100µg/ml
streptomycin (GIBCO). All surfaces were coated with a solution
of 0.5 mg/ml poly-l-lysine (MW 30,000–70,000; Sigma) in 0.05 M
sodium borate, pH 8.0 overnight at room temperature and were
washed thoroughly with distilled water before adding the culture
medium. Cultures were maintained in an incubator with 5% CO2
at 37˚C during the whole culturing period. After attachment of
cells, the medium was replaced by serum-free Neurobasal medium
(GIBCO) supplemented with 2% v/v B-27 (Invitrogen), 2 mM glu-
tamine (GIBCO), 1.2% d-glucose (Sigma), 100 U/ml penicillin,
and 100µg/ml streptomycin.
Hippocampal neurons were used for experiments mostly
between 14 and 22 DIV (days in vitro), whereas cortical neurons
were used at 7 DIV.
CELL CULTURE CONDITIONS FOR STUDIES WITH INSULIN
Hippocampal neurons were grown in six-well culture plates either
in normal Neurobasal medium supplemented with 2%v/v B-
27, 2 mM glutamine, 1.2% d-glucose, 100 U/ml penicillin and
100µg/ml streptomycin, or in insulin-free medium consisting of
Neurobasal medium and all ingredients such as indicated above,
except commercially available insulin-free B-27 (Cat. No. 05-
0129SA, GIBCO). For insulin deprivation experiments neurons
were initially grown in standard Neurobasal medium in order to
support optimal growth. At 18 DIV, one third of medium was
replaced with pre-warmed insulin-free medium. This procedure
was repeated on the following 2 days. On the fourth day neurons
were harvested using TRIzol reagent (Cat. No. T9424, Sigma, Ger-
many) to stabilize the mRNA and samples were frozen at −80˚C
until further proceeding. For insulin boost experiments 21 DIV
neurons grown in standard Neurobasal medium were challenged
once with 100µg/ml of insulin (Cat. No. I9278, Sigma, Germany)
added to the growth medium for 1, 4, and 24 h. After the individual
time periods, neurons were again harvested with TRIzol reagent.
Additionally, we cultured hippocampal neurons in insulin-free
medium from 0 DIV onward in comparison with the same batch of
cells in standard growth medium and harvested the cells at 21 DIV
using TRIzol reagent.
ISOLATION OF mRNA FROM RODENT AND HUMAN BRAIN SAMPLES
Three rats were sacrificed and their brains were isolated. Tis-
sues were immediately shock frozen in liquid nitrogen. Subse-
quently, different brain regions (cerebellum, hippocampus, stria-
tum, frontal cortex, parietal cortex, olfactory bulb) were dissected
under the microscope.
For human samples tissues were obtained from the Pathology
Department, Medical University of Vienna, Austria in agreement
with the Ethical Committee of the Medical University of Vienna
(EK: 987/2010). Samples were from three male individuals 62,
73, and 70 years of age, who have died of lung cancer, chronic
obstructive airway disease and myocardial infarction, respectively.
About 30 mg of each human brain tissue (cerebellum, frontal
cortex, parietal cortex, occipital lobe, temporal cortex, hippocam-
pus, olfactory bulb, thalamus, hypothalamus, stem ganglia) was
put into TRIzol reagent and RNA was isolated as described below.
REAL-TIME QUANTITATIVE PCR
RNA (from neuronal cells or brain tissues stabilized with TRI-
zol reagent) was extracted using chloroform-isopropanol with
phase-separation by centrifugation. Subsequently, 1µg of total
RNA was reverse-transcribed (1 h, 55˚C) using MLV reverse tran-
scriptase (Invitrogen). The diluted (1:3) cDNA was used as a tem-
plate together with TaqMan 2xMasterMix (Lot: N10545, Applied
Biosystems) and with TaqMan probes specific for rat-Scgn (No.
Rn01529973_m1), human-SCGN (No. Hs00907373_m1), rat-Tau
(No: Rn01495715_m1), rat-SNAP-25 (No. Rn00578534_m1), rat-
Syt-1 (No. Rn00436852_m1), rat-Sgk (N0. Rn00570285_m1),
and rat-Ins-1 (No: Rn02121433_g1). The RT-qPCR measure-
ment was carried out at the StepOnePlus Fast Real-Time PCR
System (Applied Biosystems). Expression values were calculated
according to the ∆∆CT method or with calculation of the copy
number using rat-Scgn plasmid as standard. As housekeeping
genes, the TaqMan Ubc probe (No. Rn01789812_g1) was used
for samples from neuronal cell cultures and the Gapdh probe (No:
Rn01775763_g1 for rat, Hs02758991_g1 for human) was used in
brain samples.
GST PULL-DOWN ASSAY FROM RAT BRAIN
GST pull-down assays were performed essentially in the same
manner as described in (Maj et al., 2010). Briefly, human GST-
SCGN fusion protein or GST only was loaded onto Glutathione-
Sepharose 4B beads (Cat. No.17-0756-01, Healthcare Biosciences).
Whole rat brain tissue was homogenized and 200 mg was lysed in
2000µl TPBS including 1 mM PMSF in Lysing Matrix A (MP Bio-
medicals Cat.nr. 6910-050) tubes using the Precellys 24 lysis and
homogenization device set at 5000 for 20 s. The resultant lysate
was centrifuged at 12,000× g for 10 min and incubated with GST-
and GST-SCGN-Sepharose beads according to Maj et al. (2010).
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In brief, 35µl of beads were incubated with 400µl of lysate at 4˚C
for 90 min under constant rotation. In order to test for calcium
dependence of the interaction between Secretagogin and Tau pro-
tein, we used different concentrations of EDTA (0, 2.5, 5.0, 7.5,
and 10.0 mM) in the lysate upon incubation with GST-SCGN-
Sepharose beads. After three washes with TPBS including 1 mM
PMSF bound proteins were eluted with 10 mM EDTA. The eluates
were then further processed for Western blot analysis. 15% of the
lysate used for pull-downs was loaded as input control.
IMMUNOPRECIPITATION
PureProteom protein G magnetic beads (100µl, Millipore) were
washed in PBS and loaded with D24 mAb by incubation at
RT for 60 min under constant rotation (negative control: unre-
lated isotype mAb) and afterwards washed with 0.2 M sodium
borate pH 9.0. Antibodies bound to the beads were chemically
crosslinked using 40 mM dimethyl pimelidate dihydrochloride
(DMP, Sigma) for 1 h at RT. Excess of DMP was neutralized with
0.2 M ethanolamine pH 8.0 followed by washes with PBS. Before
use, beads were pre-eluted with 0.1 M glycine pH 2.0.
For immunoprecipitation, antibody-coupled beads were incu-
bated with brain extract (prepared as for GST pull-down experi-
ments) and incubated at 4˚C for 2 h under constant rotation. After
three washes with TPBS, bound protein was eluted with 100 mM
glycine pH 2.0. Eluates were loaded onto SDS-PAGE, transferred
onto nitrocellulose and developed with rabbit anti-SCGN and
anti-pan-Tau, respectively.
SUBCELLULAR FRACTIONATION ON A SUCROSE GRADIENT
One-hundred milligrams of whole rat tissue were homogenized
in 1.7 ml sucrose buffer (250 mM sucrose, 20 mM Tris/HCl pH
7.4, 1 mM EDTA, protease inhibitors). Cell nuclei and large aggre-
gates were pelleted by centrifugation at 10,000× g for 10 min. The
entire supernatant was loaded onto a discontinuous sucrose gradi-
ent in polyAllomer centrifuge tubes (14 mm× 95 mm, Beckman).
Following centrifugation (2 h at 4˚C) at 40,000 rpm using a SW40
Ti rotor in a L-80 ultracentrifuge, the gradient was fractionated in
500µl aliquots using a peristaltic pump starting at the bottom of
the tube. Individual fractions were subjected to immunoblotting
using antibodies for Scgn, SNAP-25, α-tubulin, and pan-Tau.
RESULTS
EXPRESSION OF SECRETAGOGIN IN THE MAMMALIAN BRAIN
Expression of Secretagogin has been found at the highest level
in pancreatic beta cells and in neuroendocrine cells of the CNS
(Wagner et al., 2000; Gartner et al., 2001; Attems and Jellinger,
2006; Mulder et al., 2010). Studies on mouse and human brain
tissue indicated a varying expression pattern in mice and men.
However, until now no detailed comparative analysis of the Secre-
tagogin distribution in mammalian brain has been presented. We
used quantitative real-time PCR (RT-qPCR) to measure relative
Secretagogin mRNA levels in different major areas of rat brain and
compared it to tissue from the corresponding areas in human brain
(Figure 1). Interestingly, while human brain reveals an expression
maximum in the cerebellum (Figure 1A), in rat brain by far the
highest expression of Secretagogin is found in the olfactory bulb
(Figure 1B). This is also the case in mouse brain (Mulder et al.,
2009). Significant expression of Secretagogin is also found in the
hippocampus of humans and rodents confirming previous stud-
ies (Gartner et al., 2001; Attems et al., 2007; Mulder et al., 2009).
The same pattern translates into differences of protein expres-
sion especially with regard to expression maxima in cerebellum
and olfactory bulb respectively, which we confirmed by Western
blotting also for human and rat brain (Inserts in Figures 1A,B).
Differences between mRNA levels and protein have been found
in other areas with lower expression levels. β-actin was used as
internal standard. For all of our immunological studies we used a
rabbit polyclonal anti-SCGN antibody generated in our lab. The
antibody specificity has been tested for individual applications, like
Western blotting, immunocytochemistry of fixed cells in culture,
and immunohistochemistry on paraffin-embedded human and
rat tissue and paraformaldehyde-fixed rat tissue (Figures 2A,B).
CELL TYPE SPECIFIC EXPRESSION OF SECRETAGOGIN IN HUMAN
CEREBELLUM AND RAT OLFACTORY BULB
The neuronal circuits and cell identities are well defined in cere-
bellum and olfactory bulb. In order to investigate the distribution
of Secretagogin in the different cell types of human cerebel-
lum and rat olfactory bulb we performed immunohistochemistry
from paraffin-embedded slices of the respective tissues. Human
cerebellum reveals especially high Secretagogin expression in the
molecular layer (Figure 3A). Positive neurons have previously
been identified as interneurons of the basket and stellate cell type
(Gartner et al., 2001). Purkinje cell bodies are faintly staining posi-
tive, granule cells are free from intracellular Secretagogin staining,
while interneurons of the granule cell layer are Secretagogin-
positive (Figures 3A,C). A contribution of a small cross-reactivity
of our Secretagogin antibody to faint stainings (like in Purkinje
cell bodies) cannot be fully excluded.
The outer part of the olfactory bulb is also organized in well
defined cell layers. In rat, many neurites (probably dendrites and
axons) and some cell bodies stain positive in the glomerular layer
and in the external plexiform layer. However, within the granular
cell layer mainly cell bodies and only few neurites are Secretagogin-
positive. From the routine experience with our antibody we con-
sider the faint staining of mitral cell bodies as slightly positive
for Secretagogin. But a staining due to weak cross-reactivity again
cannot be fully excluded (Figures 3B,D).
HOTSPOTS OF SECRETAGOGIN-POSITIVE CELLS IN SPECIALIZED
AREAS OF RAT BRAIN
As previous studies describe Secretagogin in the mouse and human
nervous system, we extended our investigations to rat brain.
Although both mice and rats are rodents, differences in Secret-
agogin distribution cannot be excluded. Also, recent studies on
mouse focused only on special areas in the mouse brain (Mulder
et al., 2009, 2010).
Therefore we stained coronal sections from rat brain with
anti-Secretagogin antibody and counterstained with hematoxylin
(Figure 4). Secretagogin-positive (Scgn+) cells frequently occur
in cell clusters in addition to positive cells scattered over larger
areas. As described for mouse, also in rats peripheral cell layers
of the olfactory bulb are Scgn+. When choosing a more lat-
eral layers in addition to the cell layers described in Figure 3,
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FIGURE 1 | Expression of Secretagogin in different regions of human
and rat brain. Tissues from different brain areas were analyzed for relative
Secretagogin gene and protein expression by RT-qPCR and Western
blotting. (A) Human post-mortem tissues from three individuals were
analyzed with regard to the following specific brain regions: cerebellum,
frontal cortex, parietal cortex, hippocampus, thalamus, and olfactory bulb.
Western blot analysis was performed from tissue of white matter,
thalamus, hypothalamus, hippocampus, stem ganglia, cerebellum, frontal
cortex, parietal cortex, and occipital cortex. Equal protein loading was
verified by staining with β-actin antibody. (B) Rat brain tissues from three
adult rats were dissected and analyzed from cerebellum, frontal cortex,
parietal cortex, hippocampus, striatum, and olfactory bulb. A
representative Western blot of equal amounts of protein from cerebellum,
frontal cortex, parietal cortex, hippocampus, striatum, and olfactory bulb is
shown on the right. β-actin immunostaining was again used as loading
control.
seemingly unordered patches of strong Scgn+ cells were observed
(Figure 4A). Moving in caudal direction we found strong stain-
ing lining the surface above the optic nerve (Figure 4B). Further
positive nuclei are the supraoptic nuclei on both sides of the
optic chiasm and the suprachiasmatic nuclei of the hypothala-
mus (Figure 4C). In addition some islets of clustered cells can be
seen in this figure, which we could not unambiguously attribute to
a defined anatomical structure (arrows). A highlighted area is also
the paraventricular nucleus (Figure 4D). Prominent Secretagogin
staining has been observed in hippocampal areas CA1–CA3, with
almost no staining in dentate gyrus (Figure 4E). A magnification
of an area in CA1 reveals staining of hippocampal pyramidal cell
bodies and more positive intercalated interneurons as defined later
in co-stainings with antibodies for marker proteins in Figure 5
(Figure 4E1). Moving further in caudal direction again accumu-
lations of strongly stained cells were detected in the outer cortex
around the posterolateral cortical amygdaloid area (Figure 4F).
A magnification of the positive cell patch reveals strong stain-
ing of neuronal processes in this area (Figure 4F1). Further a
meshwork of positive processes with some scattered Scgn+ cells
is observed in the basal ganglia with caudate putamen shown in
(Figure 4G). Patches of positive cells are seen at the beginning
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FIGURE 2 | Secretagogin antibody specificity. (A) A Jurkat cell line (1) was
stably transfected with human Secretagogin (2). Immunocytochemistry and
Western blot analysis from cell lysates reveal the specificity of the antibody in
this heterologous cell line for both techniques. (B) Secretagogin antibody
specificity test on rat brain slices: our Secretagogin antibody was used to
stain rat brain slices in the CA1 region of the hippocampus without (upper
panel) and with pre-absorption (lower panel) with purified antigen.
Secretagogin staining is shown in green and nuclear staining (DAPI) in blue.
FIGURE 3 | Subcellular distribution of Secretagogin-positive cells in
human cerebellum and rat olfactory bulb. Paraffin sections from human
cerebellum (A) and rat olfactory bulb (B) were processed for Secretagogin
immunoreactivity (DAB staining in brown) and counterstained with Mayer’s
Hemalaun (blue). Human cerebellum reveals positive Secretagogin staining
of interneurons in the molecular layer (ML) and the granule cell layer (GCL).
Granule cells are immuno-negative and Purkinje cells bodies revealed faint
positive staining (PCL). Actual expression of Secretagogin in Purkinje cells
would need verification by single cell analysis. The rat olfactory bulb shows
Secretagogin-positive cells in the glomerular layer (GL), the external
plexiform layer (EPL), and the granular cell layer (GrO). The mitral cell bodies
(indicated by an arrow, MIL) seem to be very weakly positive. Scale bars:
200µm. Magnifications of the human Purkinje cell layer and rat mitral cells
are shown in (C,D) respectively. Principal cells are indicated by arrows.
Scale bars: 20µm.
of the hippocampal formation close to the ventricle. The same
figure reveals Scgn+ cells in the habenular region, which is located
ventral to the hippocampus, again near the ventricle (Figure 4H).
The lateral amygdala nucleus reveals also quite a few positive cells
(not shown). Two nuclei, arrays of surface lining cells and scattered
Scgn+ cells were found in the medulla oblongata (Figure 4I and
magnification in Figure 4I1). Finally we also found the superior
colliculus as a Scgn+ area (Figure 4J). Larger magnifications of
Scgn+ cells in different areas are shown in (Figures 4K,E1).
SECRETAGOGIN AND OTHER CALCIUM BINDING PROTEINS
Coronal sections revealing the hippocampal formation were co-
stained for Secretagogin and other known CBPs like Parvalbumin,
Calbindin D28k, and Calretinin (Figure 5).
The antibodies mostly recognized different cell popula-
tions with occasional overlaps like co-expression of Parvalbu-
min and Secretagogin in interneurons of the CA1-3 regions
(Figures 5A–C), and Calbindin-Secretagogin co-expression in
young, possibly migrating cells (Figure 5D). Frequently, patches of
Secretagogin-positive cells are in close vicinity of patches of neu-
rons that stain positive for another CPB. This can nicely be shown
in the habenula, where large groups of Secretagogin-positive cells
are flanked by groups of Calbindin or Calretinin-positive cells
(Figures 5E,F).
SUBCELLULAR LOCALIZATION OF SECRETAGOGIN
We observed some degree of colocalization of Parvalbumin-
positive (inter-)neurons with Secretagogin in rat hippocampus.
But cells, that co-expressed Parvalbumin and Secretagogin mostly
revealed a different subcellular staining pattern for both pro-
teins (Figures 5A–C). While Parvalbumin always stained the
soma homogenously, Secretagogin frequently seemed to be accu-
mulated on subcellular structures (Figure 5C). In order to
visualize the different subcellular distribution we performed
a high resolution z-stack with a confocal microscope of a
Parvalbumin/Secretagogin-positive cell from a rat brain slice in the
CA1 region of the hippocampus and show the three-dimensional
reconstruction in a movie (see Movie S1 in Supplementary
Material).
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FIGURE 4 | Subregional expression of Secretagogin in rat brain.
Representative sections from rat brain were stained for Secretagogin
immunoreactivity and counterstained with hematoxylin. Panels represent the
following brain areas: (A) olfactory bulb, arrow pointing to a patch of strong
Scgn+ cells. Scale bar: 500µm. (B) Medial septal nucleus. Scale bar: 500µm.
(C) Supraoptic nucleus (SON) and Suprachiasmatic nucleus (SCN). Scale bar:
500µm. (D) Paraventricular nucleus (PVN). Scale bar: 400µm. (E)
Hippocampus. Scale bar: 500µm. (E1) Magnification of hippocampal neurons
in CA1. Scale bar: 10µm. (F) Lateral amygdaloid nucleus (indicated by box).
Scale bar: 500µm. (F1) Magnification of the region indicated in (F). Scale bar:
100µm. (G) Cells in caudate putamen. Scale bar: 100µm. (H) Panel reveals
two Scgn+ areas: beginning of hippocampal CA1 region (HIP CA1) and
habenula (HAB). Scale bar: 400µm. (I) Medulla oblongata. Scale bar: 500µm.
(I1) Magnification of a strongly Scgn+ nucleus in medulla oblongata as
indicated in (I). Scale bar: 25µm. (J) Superior colliculus (SC). Scale bar:
500µm. (K) Cells around the lateral ventricle. Scale bar: 25µm.
To further investigate the structures, that Secretagogin seems
to be associated with, we stained for compartmental maker pro-
teins localized in the ER or Golgi apparatus. The marker GM130
is an intracellular peripheral membrane protein associated with
the cis-Golgi network and vesicles derived from ER and asso-
ciated with cis-Golgi. We found, that Secretagogin frequently
stained clusters in immediate apposition to GM130 clusters. In
contrast, Secretagogin clusters seemed not to be spatially associ-
ated with staining for the ER marker GRP78 (Figure 6). The close
localization of Secretagogin and GM130 is again visualized in a
three-dimensional reconstruction based on z-stack imaging (see
Movie S2 in Supplementary Material).
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FIGURE 5 | Secretagogin and other CBPs. PFA-fixed rat brain slices were
immunostained for Secretagogin (Scgn: green) and other CBPs (red) and
processed for immunofluorescence. (A-C) Hippocampal CA1 region:
Secretagogin (green), Parvalbumin (PV, red). (A) Scale bar: 100µm. (B)
Arrows indicate co-expression of Scgn and PV; green arrow: Scgn only, red
arrow: PV only; yellow arrow: co-expression of Scgn and PV in a single
neuron. Scale bar: 50µm. (C) Larger magnification of Scgn/PV co-expressing
neurons indicates a distinct subcellular distribution. Scale bar: 7.5µm. (D)
Secretagogin-positive neurons near the ventricle. Secretagogin (green),
Calbindin D28k (red). Scale bar: 25µm. (E) Habenula: Secretagogin (green),
Calbindin D28k (red). Scale bar: 75µm. (F) Habenula: Secretagogin (green),
Calretinin (red). Scale bar: 100µm.
FIGURE 6 | Subcellular localization of Secretagogin. Rat brain slices were
processed for immunofluorescence with anti-Secretagogin antibody (green)
and antibodies for marker proteins of subcellular compartments (red): (A)
GM130 (for cis-Golgi compartments) and (B) GRP78 (for Endoplasmatic
Reticulum). White arrows in upper panel indicate close spatial apposition of
Secretagogin clusters and GM130. Scale bar: 10µm.
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FIGURE 7 | Fractionation of rat hippocampal extract by sucrose
density gradient. The fractionation and sampling was done as described in
the methods section. Fractions were immunoblotted and proteins detected
with antibodies for Tau protein (pan-Tau), alpha-tubulin, synaptic
vesicle-associated protein SNAP-25 and Secretagogin. Fractions of high
density hold the membrane-associated components and fractions with
lower sucrose concentration contain soluble proteins of the cytosol.
Calculated sucrose concentrations of collected aliquots are indicated on top
of the panel. The experiment was repeated three times with similar results.
We also used sucrose density centrifugation of rat hippocampal
tissue extracts to separate membrane-bound proteins from solu-
ble proteins. Secretagogin was found in the membrane-fraction as
well as in the cytosolic fraction (Figure 7).
SECRETAGOGIN AND TAU PROTEIN
Secretagogin has previously been shown to interact with an iso-
form of Tau in an insulinoma cell type (Maj et al., 2010). We
now investigated, if this interaction is also present in rat brain. We
immunoprecipitated Secretagogin from brain extracts and per-
formed a Western blot. The co-precipitation of Tau was confirmed
by incubation with a pan-Tau antibody (Figure 8A).
The dependence of this interaction on the presence of Ca2+ was
verified with an in vitro pull-down assay. A GST-fusion protein of
full-length Secretagogin was incubated with rat brain extracts in
the absence or presence of different concentrations of EDTA. Tau
protein could only be found to be associated with GST-SCGN in
the complete absence of EDTA, indicating the Ca2+-dependence
of this interaction (Figure 8B).
INSULIN REGULATES SECRETAGOGIN EXPRESSION IN VITRO
Insulin is a conventional growth factor for cultured cells. A vast
number of publications deals with the roles of insulin in the ner-
vous system affecting neuronal growth, neuroprotection, neuro-
transmitter release, activation of Ca2+ channels, and more (Unger
et al., 1991; Zhao and Alkon, 2001). On the other hand, Secreta-
gogin has been discovered and is now well-established as Ca2+
sensor in insulin secretion from pancreatic beta cells (Wagner
et al., 2000). Interestingly, Secretagogin mRNA transcript levels
are significantly higher in a pancreatic tissue obtained from Goto–
Kakizaki rats (an animal model for type 2 diabetes) when com-
pared to non-diabetic control Wistar rats (Bazwinsky-Wutschke
et al., 2010). On this basis, we aimed to investigate the effects of
insulin on the expression of Secretagogin in a rat primary neuronal
cell culture.
Hippocampal neurons were grown in standard Neurobasal
medium with B-27 supplement (with a basal insulin concentra-
tion of 40 pg/ml in the final medium as indicated in the data sheet
of the manufacturer). When synaptogenesis was finished, a strong
insulin boost (final concentration: 100µg/ml) or a gentle – but
almost complete – insulin deprivation was performed as described
in the Section “Materials and Methods.”
Insulin deprivation from normal culture medium over 3 days
caused a significant decline in Secretagogin gene expression level to
as little as 20% of control levels already on the first day after feeding
with insulin-free Neurobasal/B-27 medium (Figure 9A), whereas a
single insulin boost caused a steady highly significant increase in its
expression levels after 24 h (Figure 9B). In addition, we measured
the mRNA level of other proteins similarly involved in exocyto-
sis processes, such as SNAP-25 and synaptotagmin-1. These levels
were also significantly increased by the insulin boost (not shown).
All measurements were related to housekeeping genes.
As insulin is a major control factor of the energy status, we
also checked if addition of a high glucose concentration to the
medium has an effect on Secretagogin gene expression level. We
expected that the effect of glucose would be rather fast, as it is
readily taken up by cells via transporters and metabolized quite
fast. One hour after the addition of glucose to a final concen-
tration of 50 mM we harvested the cells and determined the
expression level of endogenous Secretagogin mRNA, which had
significantly declined by 56%. The data from the glucose-boost
experiments show that glucose decreases Secretagogin expression
(Figure 9C).
DISCUSSION
In the present study we report novel immunocytochemistry
and functional data of the CBP Secretagogin in the context of
neuronal cells. Secretagogin has been shown to be involved in
insulin release from pancreatic beta cells, but it is also highly
expressed in neurons – another type of excitable cells. Studies
in flies have revealed that the pancreatic islet has evolutionarily
developed from an ancestral insulin-producing neuron (Rulif-
son et al., 2002; Craft and Watson, 2004). The intrinsic prop-
erties of the protein might be similar in different locations, but
the functional aspects most probably have evolved independently
in the endocrine and nervous system. A large number of CBPs
exist with different molecular properties. Some CBPs have been
used as markers for neuronal cell types especially to group the
enormous heterogeneity of cells in the nervous system before
other measurable characteristics like unambiguous morpholo-
gies or firing patterns became accessible. More recently, those
CBPs received focused attention with regard to their individual
functional properties. Their very limited co-localization indi-
cates, that different cell types might tune the expression accord-
ing to their needs based on the molecular properties of the
CBPs.
Secretagogin belongs to a family of hexa EF-hand CBPs and
is capable of binding four Ca2+ ions at physiological intracel-
lular Ca2+ levels with a binding affinity of Ca2+ similar to
Frontiers in Molecular Neuroscience www.frontiersin.org August 2012 | Volume 5 | Article 84 | 10
Maj et al. Calcium binding protein Secretagogin in neurons
FIGURE 8 | Calcium-dependent association of Secretagogin withTau
protein. (A) Immunoprecipitation from brain extracts using anti-Secretagogin
antibody followed by immunoblot with pan-Tau antibody (upper panel) and
anti-Secretagogin antibody (lower panel). The input-lane contains 15% of the
whole extract used for immunoprecipitation. For a negative control an equal
amount of an unrelated antibody was used for the immunoprecipitation. (B)
Pull-down experiment from rat brain using GST-SCGN fusion protein in the
presence or absence of EDTA. Upper panel: Coomassie staining of GST-SCGN
fusion protein, which was used for pull-down assays. Lower panel:
Immunoblot with pan-Tau antibody. The input-lane contains 15% of the extract
used for individual pull-down experiments. All experiments were repeated at
least three times.
other nCBPs (Rogstam et al., 2007). High Secretagogin expres-
sion was reported not only in the pancreatic tissue, but also in
subpopulations of developing or adult neurons (Gartner et al.,
2001; Mulder et al., 2009, 2010). As the expression of Secre-
tagogin is restricted to specialized brain areas, it is especially
motivating to research for a context of Secretagogin expres-
sion and functional aspects of these neuronal populations in the
organism. Intrinsic mechanisms of activation (also with regard
to Mg2+ as a co-factor), subcellular location, and target pro-
tein specificity as investigated also for other CBPs are impor-
tant parameters in this regard (Rogstam et al., 2007; Schmidt,
2012).
In this study we characterized the distribution of Secretagogin
immunoreactivity in rat brain and in specialized areas from human
brain. The unique, but distinct Secretagogin expression pattern
within human and rodent brain presumably underlines the exis-
tence of complex and refined mechanisms of Ca2+ signaling. This
goes hand in hand with the expression of neuronal insulin and
insulin receptors. Apart from entering the CNS via the blood-brain
barrier by a receptor-mediated transport process, insulin expres-
sion is also found directly from cells of the CNS. In rodents insulin
binding is especially high in the olfactory bulb, the cerebral cor-
tex, hippocampus, hypothalamus, amygdala, and septum (Baskin
et al., 1987). Insulin receptors are also found in the substantia
nigra, basal ganglia, and frontal cortex (Unger et al., 1991; Craft
and Watson, 2004). By immunohistochemistry we could show a
high expression of Secretagogin not only in the olfactory bulb and
the hippocampal pyramidal cell layer, but also in the basal ganglia,
and with extreme density in major nuclei of the hypothalamus
(in the neurosecretory neurons of the supraoptical nucleus, the
suprachiasmatic nucleus controlling circadian rhythms, and the
paraventricular nucleus involved in the control of food-intake),
the habenula, the amygdala, the medulla oblongata, and the supe-
rior colliculus. Many neurons in the hypothalamus release peptide
hormones like oxytocin, vasopressin, vasoactive intestinal peptide,
anti-diuretic hormone, and others that are released into the blood
as well or act directly within the brain on receptors on the sur-
face of other neurons. Many of these areas have some functional
similarities and are interconnected. In analogy to insulin-releasing
pancreatic beta cells, a role of Secretagogin in neuronal hormone-
release or glucose metabolism can be hypothetically anticipated.
The habenula is a phylogenetically old area receiving input from
the limbic system, the pineal gland, and the basal ganglia. The
habenula is thought to play a part in many basic processes. It is
a relay area for olfactory stimuli and is thought to be involved
in processing of external stress, decision-making, and also sleep
(Hikosaka, 2010). The habenula seems to be especially activated
during experiences that are associated with unpleasant events,
the absence or opposite of reward, and even punishment. In
rat models of depression the glucose metabolism in the lateral
habenula has been shown to be elevated. Secretagogin knock-
out mice would be an extremely interesting model system for
investigating the role of this CPB in more complex brain-body
functions.
In relation to other CBPs, we observed only a restricted overlap
of Secretagogin with Parvalbumin and Calbindin D28k in some
areas. Even in cells expressing Secretagogin together with another
CBP, the time course of expression or the subcellular localization
might be different in development, different phases of brain activ-
ity or metabolic states. A role of Secretagogin in developing or not
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FIGURE 9 | Insulin and glucose regulate Secretagogin expression in
neuronal cell culture. Hippocampal neurons in culture were subjected to
insulin deprivation or challenged with an insulin- or glucose-boost and
analyzed for Secretagogin expression at 21 DIV. Relative amounts of
Secretagogin mRNA were determined by RT-qPCR after insulin deprivation
(A), insulin boost (B), and glucose boost (C) at different time points after
treatment (n=3).
terminally differentiated neurons has been proposed and shown
previously in some areas like the olfactory bulb (Mulder et al.,
2009, 2010). In our studies we also observed Secretagogin-positive
neurons, that are probably not terminally differentiated in areas
known to contain migrating neurons (as shown in Figure 4K)
and sometimes also in areas with few other neuronal cell bodies
like the corpus callosum (not shown). We think, that this issue
needs a detailed study on its own. It might be possible, that neu-
rons also switch the expression of their CBPs in the course of
development.
In mature neurons of the CA1 pyramidal cell layer a compart-
mental association of Secretagogin could be observed in rat brain
slices. Secretagogin does neither possess a classical signal pepti-
dase cleavage site that would be a sign for targeting to the ER nor
a consensus site for myristoylation for membrane attachment like
in many other CBPs. However, we could show a direct opposition
of strong Secretagogin and GM130 immunoreactivity indicating
an association with cis-Golgi vesicles or compartments. The exact
identification of these compartments and the form of interaction
needs further investigations.
It is accepted knowledge that Ca2+ homeostasis is shifted dur-
ing normal aging and is especially disturbed in many neurodegen-
erative disorders. Thus the intimate connection between intracel-
lular Ca2+ levels and diseases of the CNS reinforces the importance
of maintaining the delicate balance of Ca2+ levels within the
brain, and the important role of CBPs in this matter. Of special
interest with regard to Alzheimer’s disease further studies on the
Secretagogin-Tau interaction in vitro should not be neglected. A
neuroprotective role of Secretagogin in the human hippocampus
has been previously suggested, as Secretagogin expressing neurons
have been shown to be free of the pathological hyperphosphory-
lated form of Tau in AD brains (Attems et al., 2008). In particular
the Secretagogin expression level in human hippocampus from AD
patients versus healthy individuals seems to remain unchanged for
longer periods of the developing illness, implying that these neu-
rons might be more resistant to pathological deregulation and
cell death (Attems et al., 2008). A causal link between Secreta-
gogin expression and neuroprotection has not been shown. But
also, if this hypothesis holds true, a contribution of other factors
might as well play a significant role. Unpublished observations
indicated that Secretagogin seems to be upregulated in cells close
to amyloid plaques what can be interpreted as a protective adap-
tation with the aim of regeneration. This promising hints have
led to further studies on the communication between Secreta-
gogin and Tau using transgenic animals (Attems et al., 2011).
The (P301L) Tau transgenic mice are a model system for the
Tau-pathological aspects in AD in the absence of Aβplaques. Inter-
estingly, overexpression of this mutant (pathological form of) Tau
protein significantly reduced Secretagogin expression in the brains
of these mice.
As Secretagogin has been shown to be involved in insulin release
from pancreatic cells, a possible link between Secretagogin and
insulin in the brain can be imagined. Insulin together with insulin
growth factor-1 (IGF-1) belongs to the main growth factors in situ,
and therefore it is also added to the medium for neuronal cell cul-
turing in vitro. The downstream signaling cascades are relatively
well known. On the other hand, Secretagogin not only influences
insulin synthesis in and secretion from endocrine cells, but it might
also play a role in energy household and metabolism. Here we show
that Secretagogin expression is increased in response to insulin
in vitro supporting the idea that levels of Secretagogin could be
regulated by circulating insulin or via different factors influenc-
ing insulin signaling pathways in the brain under normal and
pathological conditions.
In this study we provide new insights into the expression pat-
terns of Secretagogin in rodent’s (rat) brain that should help to
formulate new hypotheses concerning the role of this CBP in the
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nervous system. Neuronal cell culture systems have meanwhile
undergone further technical advancement and protocols are avail-
able for many more cell types of the CNS compared to the recent
past. These primary neurons in vitro can be simple model systems
to study the cellular functions and dynamics of Secretagogin. A
high translational relevance of further knowledge on this protein
is already apparent.
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Movie S1 |Three-dimensional reconstruction of a hippocampal interneuron
co-expressing Parvalbumin and Secretagogin. Rat brain slices were
immunostained for Secretagogin (green) and Parvalbumin (red). Z-stacks were
taken on a Leica confocal microscope from a Parvalbumin-positive interneuron
in the CA1 region of the hippocampus co-expressing Secretagogin. The different
subcellular distribution of both CBPs becomes clearly visible.
Movie S2 | Subcellular association of Secretagogin with cis-Golgi marker
GM130. Rat brain slices were immunostained for Secretagogin (green) and
GM130 (red). Z-stacks were taken on a Leica confocal microscope and
recombined in a three-dimensional reconstruction of the cell. A non-random
spatial proximity of compartment- or subcellular structure-associated
Secretagogin and GM130 becomes evident.
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